Changing hepatitis A epidemiology and the need for vaccination in Korea

Asian Pacific Journal of Allergy and Immunology

Volumn 22, Issue 4, 2004, Pages 237-242

  Kang, Jin Han ^a   Lee, Kyung Yil ^b   Kim, Chang Hwi ^c   Sim, Derrick ^d  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

^d GLAXOSMITHKLINE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE;

AGE; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; EPIDEMIC; HEPATITIS A; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INJECTION PAIN; INJECTION SITE REACTION; KOREA; MALAISE; MASS IMMUNIZATION; MORBIDITY; QUALITY OF LIFE; RISK FACTOR; SANITATION; SEROPREVALENCE; SOCIOECONOMICS; VACCINATION;

DEVELOPING COUNTRIES; DISEASE OUTBREAKS; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; KOREA; MASS IMMUNIZATION;

EID: 14844345811     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use Exp Rev Vaccines 2002; 1: 9-23.
2. Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA 2001; 286: 2968-73.
3. Hepatitis A vaccines. WHO position paper. Weekly Epidemiological Record 2000; 75: 37-44.
4. VHPB Recommendations and Consensus statements. Accessed on 21 August 2003 at http://www.vhpb.org/recomm.html.
5. Scheifele DW, Ochnio J. Hepatitis A vaccine: Is it being used to best advantage? Can Med Assoc J 2002; 167: 44-5.
6. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22: 354-9.
7. Sohn YM, Rho HO, Park MS, et al. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med J 2000; 41: 34-9.
8. Amstrong GL. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002; 109: 839-45.
9. Kim H, Kim JH, Kim DU, et al. Study of epidemiological changes and clinical features of hepatitis A in children living in Kyung-gi Province (1988 to 1998). Korean J Pediatr Infect Dis 1998; 5: 230-8.
10. Kunasol P. Cooksley G, Chan VF, et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Public Health 1998; 29: 255-62.
11. Barzaga NG. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 2000; 18: S61-4.
12. Chin KP, Lok AS, Wong LS, Lai CL, Wu PC. Current seroepidemiology of hepatitis A in Hong Kong. J Med Virol 1991; 34: 191-3.
13. Poovorawan Y, Vimolkej T, Chongsrisawat V, Theamboonlers A, Chumdermpadetsuk S. The declining pattern of seroepidemiology of hepatitis A virus infection among adolescents in Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1997; 28: 154-7.
14. Poovorawan Y, Theamboonlers A, Sinlaparatsamee, S et al. Increasing susceptibility to HAV among members of the young generation in Thailand. Asian Pac J Allergy Immunol 2000; 18: 249-53.
15. Goh KT, Wong LYM, Oon CJ, Kumarapathy S. The prevalence of antibody to hepatitis A virus in Singapore. Asia Pac J Public Health 1987; 1: 9-11.
16. Wang LY, Cheng YW, Chou SJ, Hsieh LL, Chen CJ. Secular trend and geographical variation in hepatitis A infection and hepatitis B carrier rate among adolescents in Taiwan: an island-wide survey. J Med Virol 1993; 39: 1-5.
17. Wang S, Liu C, Huang Y, Yang Y, Lei H. Change in hepatitis A virus seroepidemiology in Southern Taiwan: a large percentage of the population lack protective antibody. J Med Virol 2001; 64: 104-8.
18. Lee KY, Song KH, Kang JH. Seroepidemiology of hepatitis A in Taejon, Korea 1996. J Korean Pediatr Soc 1998; 41: 53-61.
19. Rosenthal P. Cost-effectiveness of hepatitis A vaccination in children. adolescents, and adults. Hepatology 2003, 37: 44-51.
20. Morbidity and Mortality Weekly Report. Prevention of hepatitis A through active or passive immunzation: recommendations of the advisory committee on immunization practices (ACIP). MMWR 1999; 48 (RR 12):1-37
21. Berge JJ, Drennan DP, Jacobs RJ. et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000; 31: 469-73.
22. Cooksley WGE. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat 2000; 7 (Suppl 1): 1-3.
23. Halliday ML, Kang LY, Zhou TK, et al. An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 1991; 164: 852-9.
24. Niu MT, Polish LB, Robertson BH, et al. Multistate outbreak of hepatitis A associated with frozen strawberries. J Infect Dis 1992; 166: 518-24.
25. Hutin YJF, Pool V, Cramer EH, et al. A multistate foodborne outbreak of hepatitis A. N Engl J Med 1999; 340: 595-602.
26. Morbidity and Mortality Weekly Report. Hepatitis A outbreak associated with green onions at a restaurant - Monaca, Pennsylvania. MMWR 2003, 52 Dispatch: 1-3.
27. Sanchez G, Pinto RM, Vanaclocha H, Bosh A. Molecular characterization of hepatitis A virus isolates from a transcontinental shellfish-borne outbreak. J Clin Microbiol 2002; 40: 4148-55.
28. Lopalco PL, Salleras L, Barbuti S, et al. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2000; 19: 470-4.
29. Epidemiological News Bulletin. A shellfish-borne outbreak of hepatitis A. 2002; 28: 55-57. Accessed 25 November 2003 at http://app.moh.gov.sg/edc/cid_94asp.
30. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 2001; 14: 38-58.
31. Epidemiology of acute hepatitis A in Singapore, 1997-2001. Epidemiological News Bulletin 2002; 28: 49-52. Accessed 25 November 2003 at http://app.moh.gov.sg/edc/cid_94asp.
32. Webster G, Barnes E, Dusheiko G, Franklin I. Protecting travellers from hepatitis A. BMJ 2001; 322: 1194-5.
33. The International Consensus Group on Hepatitis A Virus Immunity. Consensus Statement: hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 1065-71.
34. Kim CH, Pyun BY, Hong YJ, Kang JH. Immunogenicity and reactogenicity of inactivated HM175 strain hepatitis A vaccine in healthy Korean children. Korean J Pediatr Infect Dis 2000; 7: 120-8.
35. Clemens R. Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl 1): S44-9.
36. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-35.
37. Cho HJ, Lee MH, Kim JH, et al. Prevalence and persistence of transferred maternal hepatitis A antibody during the second year of life in Korean infants. Korean J Infect Dis 2001; 33: 331-7.
38. Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44: 446-51.
39. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 2000; 60: 1-7.
40. Arankalle VA, Chadha MS. Who should receive hepatitis A vaccine? J Viral Hepat 2003; 10: 157-8.
41. World Health Organization Vaccines Immunization and Biologicals. Accessed on 12 November 2003 at http://www.who.int/vaccines/GlobalSummary/Immunisation/ScheduleResult.cfm
42. Dagan R. Update from Israel, the first country to adopt hepatitis A universal immunization program. 3rd World Congress of Pediatric infectious Diseases, Santiago, Chile. 19-23 November 2002; Abstract 368.
43. Dominguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in pre-adolescents. Vaccine 2003; 21: 698-701.
44. Centers for Disease control and Prevention. National Center for Infectious Diseases. Viral hepatitis slide sets: Hepatitis A. Accessed 25 November 2003 at http://www.edc.gov/ncidod/diseases/hepatitis/index.htm.
45. Beutels P, Edmunds WJ, Antonanzas F, et al. Viral Hepatitis Prevention Board. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20: 1-7.
46. Jacobs RJ, Saab S, Meyerhoff AS, Koff RS. An economic assessment of prevaccination screening for hepatitis A and B. Public Health Rep 2003; 118: 550-8.
47. Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 2001; 34: 92-9.
48. Poovorawan Y, Chatchatee P, Chongsrisawat V. Epidemiology and prophylaxis of viral hepatitis: a global perspective. J Gastroenterol Hepatol 2002; 17 Suppl: S155-66.
49. Jacobs JR, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J 2003; 22: 904-14.
50. Rajan E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland, Am J Gastroenterol 2000; 95: 223-6.
51. Teppakdee A, Tangwitoon A, Khemasuwan D, et al. Cost-benefit analysis of hepatitis A vaccination in Thailand. Southeast Asian J Trop Med Public Health 2000; 33: 118-27.
52. Soogarun S, Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective? Southeast Asian J Trop Med Public Health 2002; 33 (Suppl 3): 145-8.